The concern of generic competition has long loomed above copyright’s blockbuster drug, PDE5 Inhibitor, sparking questions about the future of related pharmaceutical holdings. While first times saw significant returns, the exclusivity end has created the path for less expensive copies, potentially diminishing revenue and posing a real danger for s